Global estimates of diabetes prevalence for 2013 and projections for 2035
- PMID:24630390
- DOI: 10.1016/j.diabres.2013.11.002
Global estimates of diabetes prevalence for 2013 and projections for 2035
Abstract
Introduction: Diabetes is a serious and increasing global health burden and estimates of prevalence are essential for appropriate allocation of resources and monitoring of trends.
Methods: We conducted a literature search of studies reporting the age-specific prevalence for diabetes and used the Analytic Hierarchy Process to systematically select studies to generate estimates for 219 countries and territories. Estimates for countries without available source data were modelled from pooled estimates of countries that were similar in regard to geography, ethnicity, and economic development. Logistic regression was applied to generate smoothed age-specific prevalence estimates for adults 20-79 years which were then applied to population estimates for 2013 and 2035.
Results: A total of 744 data sources were considered and 174 included, representing 130 countries. In 2013, 382 million people had diabetes; this number is expected to rise to 592 million by 2035. Most people with diabetes live in low- and middle-income countries and these will experience the greatest increase in cases of diabetes over the next 22 years.
Conclusion: The new estimates of diabetes in adults confirm the large burden of diabetes, especially in developing countries. Estimates will be updated annually including the most recent, high-quality data available.
Keywords: Ageing; Development; Diabetes; Prevalence; Urbanisation.
Copyright © 2013. Published by Elsevier Ireland Ltd.
Comment in
- Determinants of gender differences in the prevalence of diabetes.Guariguata L, Shaw JE, Whiting DW, Linnenkamp U.Guariguata L, et al.Diabetes Res Clin Pract. 2014 Nov;106(2):e14-6. doi: 10.1016/j.diabres.2014.08.008. Epub 2014 Aug 15.Diabetes Res Clin Pract. 2014.PMID:25204220No abstract available.
Similar articles
- IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.Whiting DR, Guariguata L, Weil C, Shaw J.Whiting DR, et al.Diabetes Res Clin Pract. 2011 Dec;94(3):311-21. doi: 10.1016/j.diabres.2011.10.029. Epub 2011 Nov 12.Diabetes Res Clin Pract. 2011.PMID:22079683
- IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B.Cho NH, et al.Diabetes Res Clin Pract. 2018 Apr;138:271-281. doi: 10.1016/j.diabres.2018.02.023. Epub 2018 Feb 26.Diabetes Res Clin Pract. 2018.PMID:29496507
- IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ.Sun H, et al.Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6.Diabetes Res Clin Pract. 2022.PMID:34879977Free PMC article.
- Global rural diabetes prevalence: a systematic review and meta-analysis covering 1990-2012.Zabetian A, Sanchez IM, Narayan KM, Hwang CK, Ali MK.Zabetian A, et al.Diabetes Res Clin Pract. 2014 May;104(2):206-13. doi: 10.1016/j.diabres.2014.01.005. Epub 2014 Jan 14.Diabetes Res Clin Pract. 2014.PMID:24507869Review.
- Number of People with Type 2 Diabetes Mellitus in 2035 and 2050: A Modelling Study in 188 Countries.Guzman-Vilca WC, Carrillo-Larco RM.Guzman-Vilca WC, et al.Curr Diabetes Rev. 2024;21(1):e120124225603. doi: 10.2174/0115733998274323231230131843.Curr Diabetes Rev. 2024.PMID:38231048
Cited by
- Hyperglycemia and hyperlipidemia can induce morphophysiological changes in rat cardiac cell line.Varela R, Rauschert I, Romanelli G, Alberro A, Benech JC.Varela R, et al.Biochem Biophys Rep. 2021 Apr 10;26:100983. doi: 10.1016/j.bbrep.2021.100983. eCollection 2021 Jul.Biochem Biophys Rep. 2021.PMID:33912691Free PMC article.
- Effects of MK-7 Supplementation on Glycemic Status, Anthropometric Indices and Lipid Profile in Patients with Type 2 Diabetes: A Randomized Controlled Trial.Karamzad N, Faraji E, Adeli S, Carson-Chahhoud K, Azizi S, Pourghassem Gargari B.Karamzad N, et al.Diabetes Metab Syndr Obes. 2020 Jun 26;13:2239-2249. doi: 10.2147/DMSO.S253014. eCollection 2020.Diabetes Metab Syndr Obes. 2020.PMID:32617013Free PMC article.
- Acute Effects of Cocoa Flavanols on Blood Pressure and Peripheral Vascular Reactivity in Type 2 Diabetes Mellitus and Essential Hypertension: A Protocol for an Acute, Randomized, Double-Blinded, Placebo-Controlled Cross-Over Trial.Tanghe A, Celie B, Shadid S, Rietzschel E, Op 't Roodt J, Reesink KD, Heyman E, Calders P.Tanghe A, et al.Front Cardiovasc Med. 2021 Mar 15;8:602086. doi: 10.3389/fcvm.2021.602086. eCollection 2021.Front Cardiovasc Med. 2021.PMID:33791343Free PMC article.
- Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin.Choi HK, Oh M, Kim EJ, Song GS, Ghim JL, Shon JH, Kim HS, Shin JG.Choi HK, et al.Int J Clin Pharmacol Ther. 2015 Feb;53(2):147-53. doi: 10.5414/CP202197.Int J Clin Pharmacol Ther. 2015.PMID:25546164Free PMC article.Clinical Trial.
- The relationship between trust in primary healthcare providers among patients with diabetes and levels of depression and anxiety.AlRuthia Y, Alwhaibi M, Almalag H, Almosabhi L, Almuhaya M, Sales I, Albassam AA, Alharbi FA, Mansy W, Bashatah AS, Asiri Y.AlRuthia Y, et al.PLoS One. 2020 Sep 11;15(9):e0239035. doi: 10.1371/journal.pone.0239035. eCollection 2020.PLoS One. 2020.PMID:32915906Free PMC article.
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical